cover-image

BerGenBio

NO: BGBIO

NOK3115.2m market cap

NOK35.7 last close

BerGenBio is a clinical stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers. It focuses on AXL inhibitors bemcentinib (small molecule) and tilvestamab (mAb).

Investment summary

BerGenBio has presented two positive datasets for its lead asset bemcentinib in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) at ASH 2020. Following these data, we anticipate a registrational Phase III study of bemcentinib plus low-dose cytarabine (LDAC) in relapsed elderly AML patients to start in 2021. We still forecast the NDA submission for this indication in 2023 (FDA fast-track has been granted). Bemcentinib is an oral, first-in-class, highly selective AXL tyrosine kinase inhibitor in Phase II development for a range of cancers and could be the first selective AXL inhibitor to market. Data from the Phase II study in second-line NSCLC in combination with Keytruda are expected at WCLC (for details see our initiation report, Bemcentinib leading the AXL charge). We value BerGenBio at NOK59.1 per share.

Y/E Dec
Revenue (NOKm)
EBITDA (NOKm)
PBT (NOKm)
EPS (öre)
P/E (x)
P/CF (x)
2018A 2.3 (194.3) (191.7) (360.0) N/A N/A
2019A 8.9 (203.6) (199.3) (343.0) N/A N/A
2020E 0.0 (259.7) (249.1) (309.0) N/A N/A
2021E 0.0 (304.8) (300.9) (345.0) N/A N/A
Industry outlook

Understanding the tumour microenvironment and why even with initial positive response to treatment, cancers often exhibit tumour proliferation, metastasis and treatment resistance is becoming an ever-more critical focus area. The role of AXL is becoming increasingly defined in tumorigenesis, propagation and treatment resistance.

Last updated on 21/01/2021
Register to receive research on BerGenBio as it is published
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (NOKm) 716.3
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 6.3 23.5 66.5
Relative* (2.4) 4.6 64.6
52-week high/low NOK46.1/NOK11.7
*% relative to local index
Key management
Richard Godfrey CEO
Rune Skeie CFO